A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR-/- mice upon lethal virus challenge

Vaccine

Volumn 29, Issue 27, 2011, Pages 4469-4475

  Boshra, Hani ^a   Lorenzo, Gema ^a   Rodriguez, Fernando ^b   Brun, Alejandro ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria Consejo Superior de Investigaciones Científicas   (Spain)

^b CENTRE DE RECERCA EN SANITAT ANIMAL CRESA   (Spain)

Author keywords

Bunyavirus; DNA vaccines; Immunomodulation; Self adjuvant

Indexed keywords

ALPHA INTERFERON RECEPTOR; COMPLEMENT COMPONENT C3D; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; GLYCOPROTEIN; LYSOSOME INTEGRAL MEMBRANE PROTEIN 2; MEMBRANE PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BUNYAVIRUS INFECTION; CONTROLLED STUDY; GENE SEQUENCE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RIFT VALLEY FEVER BUNYAVIRUS; SURVIVAL; T LYMPHOCYTE; VIRUS IMMUNITY;

ANIMALS; ANTIBODIES, VIRAL; IMMUNIZATION; MICE; MICE, KNOCKOUT; NUCLEOPROTEINS; RECEPTOR, INTERFERON ALPHA-BETA; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; T-LYMPHOCYTES; UBIQUITIN; VACCINES, DNA; VIRAL PROTEINS; VIRAL VACCINES;

EID: 79958090918     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.043     Document Type: Article

References (47)

1. Bird B.H., Ksiazek T.G., Nichol S.T., Maclachlan N.J. Rift Valley fever virus. J Am Vet Med Assoc 2009, 234(April (7)):883-893.
2. Faye O., Diallo M., Diop D., Bezeid O.E., Ba H., Niang M., et al. Rift Valley fever outbreak with East-Central African virus lineage in Mauritania, 2003. Emerg Infect Dis 2007, 13(July (7)):1016-1023.
3. Davies F.G., Martin V. Recognizing Rift Valley fever. Vet Ital 2006, 42(January-May (1)):31-53.
4. Madani T.A., Al-Mazrou Y.Y., Al-Jeffri M.H., Mishkhas A.A., Al-Rabeah A.M., Turkistani A.M., et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis 2003, 37(October (8)):1084-1092.
5. Daubney R., Hudson J.R. Enzootic hepatitis of Rift Valley fever. J Pathol Bacteriol 1931, 34:34.
6. Meadors G.F., Gibbs P.H., Peters C.J. Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials. Vaccine 1986, 4(September (3)):179-184.
7. Kamal S.A. Pathological studies on postvaccinal reactions of Rift Valley fever in goats. Virol J 2009, 6:94.
8. Chevalier V., Pepin M., Plee L., Lancelot R. Rift Valley fever--a threat for Europe?. Euro Surveill 2010, 15(March (10)):19506.
9. Naslund J., Lagerqvist N., Habjan M., Lundkvist A., Evander M., Ahlm C., et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 2009, 385(March (2)):409-415.
10. Kortekaas J., de Boer S.M., Kant J., Vloet R.P., Antonis A.F., Moormann R.J. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 2010, 28(June (27)):4394-4401.
11. Mandell R.B., Koukuntla R., Mogler L.J., Carzoli A.K., Freiberg A.N., Holbrook M.R., et al. A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 2010, 397(February (1)):187-198.
12. Wallace D.B., Ellis C.E., Espach A., Smith S.J., Greyling R.R., Viljoen G.J. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 2006, 24(November (49-50)):7181-7189.
13. Dungu B., Louw I., Lubisi A., Hunter P., von Teichman B.F., Bouloy M. Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 2010, 28(June (29)):4581-4587.
14. Morrill J.C., Mebus C.A., Peters C.J. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 1997, 58(October (10)):1104-1109.
15. Morrill J.C., Mebus C.A., Peters C.J. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 1997, 58(October (10)):1110-1114.
16. Bhardwaj N., Heise M.T., Ross T.M. Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl Trop Dis 2010, 4(6):e725.
17. Lorenzo G., Martin-Folgar R., Hevia E., Boshra H., Brun A. Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens. Vaccine 2010, 28(April (17)):2937-2944.
18. Deyde V.M., Khristova M.L., Rollin P.E., Ksiazek T.G., Nichol S.T. Crimean-Congo hemorrhagic fever virus genomics and global diversity. J Virol 2006, 80(September (17)):8834-8842.
19. Lagerqvist N., Naslund J., Lundkvist A., Bouloy M., Ahlm C., Bucht G. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol J 2009, 6:6.
20. Rodriguez F., An L.L., Harkins S., Zhang J., Yokoyama M., Widera G., et al. DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J Virol 1998, 72(June (6)):5174-5181.
21. Wu Y., Kipps T.J. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J Immunol 1997, 159(December (12)):6037-6043.
22. Wang Q.M., Sun S.H., Hu Z.L., Zhou F.J., Yin M., Xiao C.J., et al. vaccines against tuberculosis: spacers and ubiquitin modulates cellular immune responses elicited by epitope DNA vaccine. Scand J Immunol 2004, 60(September (3)):219-225.
23. Hou Y.H., Chen J., Tong G.Z., Tian Z.J., Zhou Y.J., Li G.X., et al. A recombinant plasmid co-expressing swine ubiquitin and the GP5 encoding-gene of porcine reproductive and respiratory syndrome virus induces protective immunity in piglets. Vaccine 2008, 26(March (11)):1438-1449.
24. Rodriguez F., Zhang J., Whitton J.L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol 1997, 71(November (11)):8497-8503.
25. Gravier R., Dory D., Rodriguez F., Bougeard S., Beven V., Cariolet R., et al. Immune and protective abilities of ubiquitinated and non-ubiquitinated pseudorabies virus glycoproteins. Acta Virol 2007, 51(1):35-45.
26. Borrego B., Fernandez-Pacheco P., Ganges L., Domenech N., Fernandez-Borges N., Sobrino F., et al. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses. Vaccine 2006, 24(May (18)):3889-3899.
27. Saftig P., Klumperman J. Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function. Nat Rev Mol Cell Biol 2009, 10(September (9)):623-635.
28. Vega M.A., Rodriguez F., Segui B., Cales C., Alcalde J., Sandoval I.V. Targeting of lysosomal integral membrane protein LIMP II. The tyrosine-lacking carboxyl cytoplasmic tail of LIMP II is sufficient for direct targeting to lysosomes. J Biol Chem 1991, 266(September (25)):16269-16272.
29. Rodriguez F., Harkins S., Redwine J.M., de Pereda J.M., Whitton J.L. CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol 2001, 75(November (21)):10421-10430.
30. Fernandez-Borges N., Brun A., Whitton J.L., Parra B., Diaz-San Segundo F., Salguero F.J., et al. DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J Virol 2006, 80(October (20)):9970-9976.
31. Grewal I.S., Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998, 16:111-135.
32. Manoj S., Griebel P.J., Babiuk L.A., van Drunen Littel-van den Hurk S. Targeting with bovine CD154 enhances humoral immune responses induced by a DNA vaccine in sheep. J Immunol 2003, 170(January (2)):989-996.
33. Gares S.L., Fischer K.P., Congly S.E., Lacoste S., Addison W.R., Tyrrell D.L., et al. Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks. Clin Vaccine Immunol 2006, 13(August (8)):958-965.
34. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996, 271(January (5247)):348-350.
35. Bower J.F., Sanders K.L., Ross T.M. C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences. Curr HIV Res 2005, 3(April (2)):191-198.
36. Liang P.H., Zhang K.Q., Xu G.L., Li Y.F., Wang L.F., Nie Z.L., et al. Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth. Cancer Immunol Immunother 2010, 59(January (1)):93-101.
37. Suradhat S., Braun R.P., Lewis P.J., Babiuk L.A., van Drunen Littel-van den Hurk S., Griebel P.J., et al. Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet Immunol Immunopathol 2001, 83(November (1-2)):79-92.
38. Bouloy M., Janzen C., Vialat P., Khun H., Pavlovic J., Huerre M., et al. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J Virol 2001, 75(February (3)):1371-1377.
39. Messmer D., Kipps T.J. CD154 gene therapy for human B-cell malignancies. Ann N Y Acad Sci 2005, 1062(December):51-60.
40. Bergmann-Leitner E.S., Scheiblhofer S., Weiss R., Duncan E.H., Leitner W.W., Chen D., et al. C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Int Immunol 2005, 17(March (3)):245-255.
41. Martin-Folgar R., Lorenzo G., Boshra H., Iglesias J., Mateos F., Borrego B., et al. Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization. MAbs 2010, 2(May (3)):275-284.
42. Dalum I., Jensen M.R., Gregorius K., Thomasen C.M., Elsner H.I., Mouritsen S. Induction of cross-reactive antibodies against a self protein by immunization with a modified self protein containing a foreign T helper epitope. Mol Immunol 1997, 34(November-December (16-17)):1113-1120.
43. Li X., Sambhara S., Li C.X., Ewasyshyn M., Parrington M., Caterini J., et al. Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med 1998, 188(August (4)):681-688.
44. Zeller J.C., Nguyen N., Southern P.J. Differential immune recognition of LCMV nucleoprotein and glycoprotein in transgenic mice expressing LCMV cDNA genes. Virology 1997, 231(May (2)):290-300.
45. Sumner J.W., Fekadu M., Shaddock J.H., Esposito J.J., Bellini W.J. Protection of mice with vaccinia virus recombinants that express the rabies nucleoprotein. Virology 1991, 183(August (2)):703-710.
46. Laddy D.J., Yan J., Kutzler M., Kobasa D., Kobinger G.P., Khan A.S., et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PloS ONE 2008, 3(6):e2517.
47. Spik K., Shurtleff A., McElroy A.K., Guttieri M.C., Hooper J.W., SchmalJohn C. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 2006, 24(May (21)):4657-4666.